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The Edinburgh randomised trial of breast cancer screenng: results after
10 years of follow-up
F.E. Alexander', T.J. Anderson2, H.K. Brown', A.P.M. Forrest3, W. Hepburn',
A.E. Kirkpatrick4, C. McDonald3, B.B. Muir', R.J. Prescott', S.M. Shepherd', A. Smith' &
J. Warner'
'Department of Public Health Sciences, 2Departmelt of Pathology and 3Scottish Cancer Trials Office, The Univrsity of
Edhburgh, Medical Schol, Teviot Place, Ednburgh EH8 9AG, UK,; F4 burgh Breat Screening Clinic, SpringweUl House, 26
Ardmillan Terrace, E gh EHII 2JL, UK; 5Iformation and Statistics Diviion, Scottish Health Seices Common Services
Agency, Trinity Park House, South Trinity Road, Edinbugh EH5 3SQ, UK.
S_q The Edinburgh Randomised Trial of Bret Cancer Screning recruited 44,288 women aged 45-64
years into the initial cohort of the trial during 1978-81, and 10 years of follow-up is now pte. A total of
22,944 women were ised into the study group and were offered for 7 years; the
women formed the control group. After 10 years, breast cancer mrtaty is 14-21% lower in the study group
than in the controls dependig on the precise definiton of the end point. Thes diffces are not staiically
si nt; for breast cancer as the underying cause of death the relative risk is 0.82 (95% fi interval
0.61-1.11). Rates of localy advane and metastatic cancer substantally lower in the study group, but
screming has failed to achieve nmaked reductions rates of smal node-positive cancers Those women who
acCepe the final invitation to have been monitored over the 3 year priod pnor to thir first screen
under the UK servi screenng programme Interval cases, expresse as a proportion of the controli ,
increased from 12% in the first year to 67% in the third year. The reductio in breast caner mortality for
older women (aged at least 50 years) is the same as that for the total study group for this duration of
follow-up. For analyses of breast cancer mortafity in youngfr wome updates rruited to the trial from 1982
to 1985 (10,383 women with 6-8 years' follow-up) have been incuded. The reduction in breast cancer
mortality for women aged 45-49 years at entry was 22% (relative risk = 0.78, 95% confidence inter-
val = 0.46-1.31).
The Edinburgh Randomised Trial of Breast Cancer Screening
(Roberts et al., 1984) was started in 1978. A total of 44,288
women in Edinburgh were randomised into two groups of
approximately equal size. A total of 22,944 women entered
the study arm of the trial from 1978 to 1981; these women
were invited to participate in a screeng programme that
in ed seven annual screens by clinical examination (for
seven consecutive years) and m aphy (at the first
screen and at 2 yearly intervals). These same women formed
the Edinburgh component of the study population of the
Trial of Early Detection of Breast Cancer Screening or
TEDBC (UK Breast Cancer Detection Working Group,
1981). Mortality results for the TEDBC for 10 years of
follow-up have recently become available (UK Breast Cancer
Detection Working Group, 1993) and their data include com-
parisons of the present study group with geographical con-
trols. The control groups for the TEDBC and the Edinburgh
trial are entirely distmct
The first report of the Edinburg trial (Roberts et al.,
1990) iied results for 7 years' folow-up for breast cancer
mortality and 5 years' follow-up for breast cancer incidence.
A reduction of 17% in breast canr mortality in the study
group was observed at that time (relative risk = 0.83, 95%
confidence interval 0.58-1.18). The results of 10 years of
follow-up are now reported. In additon to the initial cohort
of the trial, younger women (aged 45-49 years) were entered
annually from 1982 to 1985; the reults of shorter periods of
follow-up for these women have been inchxled here.
Following the publication of the Forrest (1987) report,
mammographic screening for breast cancer was introduced
into National Health Service policy in 1988. Invitations to
service screening for women who had been screened during
the trial period were scheduled so that, so far as possible,
they were screened during their tenth year of follow-up and 3
years after their list trial screen. In this way we are able to
provide the first estimates from a UK population of the
frequency of interval ca for women in regular screening
whose screens are scheduled to occur at 3 yearly inter-
vals.
This report focuses on three topics: breast cancer mortality
after 10 years of folow-up, the effect of screening women
aged under 50 years and the consequences of a 3 year
inter-screenig mterval.
Method
The tria popukuion
Detailed methods have been described previously (Roberts et
al., 1984). The geographical base for the trial comprised 87
general practices within the city of Edinburgh. These were
enrolled in turn between June 1979 and December 1981
(September 1978 for one practic). As each practice joined
the trial all woren aged between 45 and 64 years and on the
practice list were admitted to form the initial cohort of the
trial. Women who attained the age of 45 after the practice
entry date and others (over 45 years of age) who moved into
the study area were entered from 1982 to 1985. In order to
maximise the numbers available for subgroup analyses of
younger women (aged 45-49 years at entry) these later en-
trants have been included in these analyses and are referred
to as updates.
In 1985, women in the trial were flagged with the General
Registry Office in Edinburgh to obtain information on cancer
incidence and death. This ensures follow-up even for women
who have moved away from Edinburgh. The present report
is restricted to women who were successfully flagged (97% of
the total).
Women who had breast cancer diagnosed before entry to
the trial are ineligible, but this was often established re-
trospectively following receipt of a death notification (see
below).
Correspondence: F.E. Alexander.
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Randomisation and screening
The 87 practices were randomised to study or control status,
which provided cluster randomisation for individual women
who derived their status within the trial from that of their
practice at entry. Women in the study group were offered
screening, and those who attended (61.3%) underwent two-
view mammography and clinical examination at their initial
visit (prevalen screen). Further screening (incidence screens)
used annual clinical examination for 6 years and included
single-oblique view mammography in alternate years. Atten-
dance rates fell with time and were just over 50% during the
final (seventh) year of fieldwork (Roberts et al., 1990).
For the majority of women who continued in screeimng
each screen occurred within 1 year of the intended time - so
that, for example, the screen in 'year 3' occurred between 2
and 3 years from survey entry; these women are described as
having 'regular' screening. The NHS introduced service
screening in Scotland in 1988 for women then aged 50-64
years. For practical and administive reasons this had to be
introduced gradually and the Edinburgh programme was
coordinated with the present trial in such a way that all
women who were still in regular screening had their first
invitation to service screening at (approximately) 3 years
after their last (year 7) trial screen; this was during their
tenth year of follow-up.
Follow-up
Apart from the collection of medical information and screen-
ing histories at the screening clinic, follow-up of women in
the two arms of the trial has been identical (Roberts et al.,
1984, 1990). For the field-work period of the trial (1978-88)
local follow-up for both breast cancer incidence and total
mortality were used as independent data sources alongside
flagging. Since then, flagging has provided the primary, and
for mortality data the only, source of follow-up. Scrutiny of
counts of death notifications from flagging suggests that
these data are virtually complete after a time lag of 6
months. Data for the present analysis were finalised in
January 1993 so that ascertaiment of relevant deaths (occur-
ring 1991 or earlier) could be ensured.
Whenever a death certifiate mentioned breast cancer as a
cause of death for a woman who had not already been
identified as a breast cancer case the trial staff sought
confirmation of diagnosis. If this occurred before survey
entry date the woman was ineligible for the trial.
Flagging for cancer incidence may be less reliable than
flagging for mortality. Therefore the entire trial cohort was
matched against the Scottish Cancer Registration Scheme
database held centrally by the Information and Statistics
Division (ISD) of the Scottish Health Services Common
Services Agency. The cancer registration database is matched
annually with the Scottish hospitals inpatient database. Link-
age with the trial database used probability matching and
included all notifications of cancer registed up to the end of
1991. These methods optimised ascetainment of breast
cancer incidence in the trial population for the full 10 years
of follow-up.
Analysis of breast cancer mortality
The primary end point for analysis is 'breast cancer mortal-
ity' and, in the initial report (Roberts et al., 1990), this was
defined to be mention of breast cancer on either part 1 or
part 2 of the death certificate. We have continued to adopt
this definition here but have introduced two alternatives.
Coding of death certificates in Scotland permits one cause to
be underlied as the undeying cause of death, and this
procedure follows WHO rule 3 informally but does not use
the systematic approach adopted in England and Wales
(OPCS, 1985). Whenever breast cancer was underlined on the
death certificte the death has been clasified as a breast
cancer death in the present analyses. We have checked all
remaining deaths of women with breast cancer diagnosed
dung the trial penod to derive two clasificatons of breast
cancer as underlying cause of death:
DJntion 1: breast cancer was the underlined cause of
death on death certificate or formal application of WHO
rules (OPCS, 1985) attributed the death to breast cancer
when a non-specific cause was underlined.
Defition 2: breast cancer was the underlined cause of
death on death certificte or another cause was underlined
but case note review identified breast cancer as the under-
lying cause.
For definition 2 doubtful cases were considered by a com-
mittee of three doctors. This was more accurate but subject
to potential bias and definition 1 has been taken as the
principal definition of the end point.
As in the previous report, deaths occurring as results of
non-epithelial cancers in the breast (e.g. sarcoma, lymphoma)
are not included in the anlysis.
Following the trial protocol (Roberts et al., 1984), the
main analysis has been of breast cancer mortality in the
whole of the initial cohort for 10 years from survey entry.
We also report the results of two subsidiary analyses focused
on possible differential effects of screening women over and
under 50 years of age. Firstly, breast cancer mortality over
the 10 year period for the initial cohort has been analysed
separately for the two age groups: 45-49 years and 50-64
years at survey entry. Secondly, we have included updates in
the analysis of younger women; women entered during
1982-83 are followed-up for 8 years and later updates for 6
years (sine randomisation was in two groups by year at
entry). The analyses to be conducted were decided in advance
of data inspection.
For the statistical analysis mortality has been expressed as
rates of breast cancer deaths per 10,000 woman-years at
risk. Rates in study and control pract were compared and
their ratio alculated. As before (Roberts et al., 1990), a
modified logistic regrsion procedure incorporated adjust-
ment for extrabinomial regression (Williams, 1982) so as to
respect the cluster randomisation. All analyses were imple-
mented in 'GLIM' and stratified by age at survey entry
(45-49, 50-54, 55-59 and 60-64 years). Where updates are
included there has been further stratification by length of
follow-up. Cumulative breast cancer mortality curves are
expressed as rates per 10,000 women entering the study but
are adjusted to take account of women-years at risk. The
general practice 'clusters' have been claified into three
groups by levels of a socioeconomic score (SEG) as in the
previous report (Roberts et al., 1990).
Analysis ofbreast cancer incidence
Staging of disease follows standard UICC clinical staging
(UICC, 4th edn, 1987) and stage 0 corresponds to carcinoma
in sitwL for cases which are stage I-H pathological inform-
ation is also provided.
Cancers det in women who had attended their last
trial screen (i.e. seventh screen, 6-7 years from entry) but
had not yet had a service screen are described as 'intervals';
cases arising in the period 36-42 months after the last trial
screen and before invitation to the service screening are
included as intervals. The proportional incidence of utterval
cancers is the ratio of the incidence rate of these interval
cancers to that observed in the control group (adjusting for
the age distribution of the population at risk).
Cumulative incidence of cancers known to be advanced in
the total trial population have been plotted by year of
follow-up for two definitions of 'advanced': firstly, UICC
stages III and IV and, secondly, that used by Tabar et al.
(1985). These figures are adjusted for wom}en-years at
risk.
Reslts
The trial population is shown in Table I with women-years
of follow-up. Of the study population 61.3% responded to
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the initial invitation to screening, but only 44.1% attended
the seventh screen. The numbers of women known to be
ineligible on account of pretrial breast cancer are also shown;
prospective ascertainment is more complete for the study
group and, to avoid consequential bias, these women have
been retained in the calculations of women-years for the
denominators.
Breast cancer mortality
There have been 250 deaths in women with breast cancer
diagnosed during the trial period, including 196 (78.4%)
cases in which breast cancer was the underlined cause on the
death certificate and which were classified as breast cancer
deaths in all analyses. Case notes were reviewed for a ran-
dom sample of 50 of these women, with the cause confirmed
in 47; three deaths were not attributable to breast cancer.
The three definitions of breast cancer death agreed,
positively (199) or negatively (23), for 222 (89%) of the 250
deaths, and the two definitions of underlying cause agreed
for 232 (94%). Patients in whom doubt about cause of death
was noted included just two of the younger women (aged
45-49 years).
Details of breast cancer mortality for the total initial
cohort are provided in Table II. The mortality rates are
lower for the study population for all definitions with reduc-
tions of 14-21%. None of the results achieved statistical
significance, and the confidence intervals are wide. For the
principal end point (breast cancer as the underlying cause
using death certificate information) the reduction was 18%
(relative risk = 0.82, 95% confidence interval 0.61-1.11).
Cumulative breast cancer mortality by year of follow-up is
shown in Figure la.
Results for subgroup analyses using the principal end point
definition are reported in Table III. These provide no
evidence that a larger mortality reduction has been achieved
in older women (i.e. those aged 50 years or more at trial
entry). When the younger women were analysed separately
(Table III and Figure lb) the total numbers of breast cancer
Table I Tnral population' and women-years of follow-up
Stud! population Control population
Age at Number of Women-years Nwnber of Women-years
entry ,omen' of folloW-up %omenb of follow-up
45-49 5795 (59) 56750 55% (32) 54588
50-54 5878 (65) 57021 5168 (40) 49603
55-59 6109 (112) 57993 5749 (56) 53872
60-64 5162 (102) 47451 4831 (49) 43758
Total 22944 (338) 219215 21344 (177) 201821
'These figures are for the initial cohort defined in the Methods
section and exclude women who were not successfully flagged;
corresponding figures for the updates aged 45-49 at entry are: study
population, 5,710 women (40,456 women-years); control population,
4,673 women (34,178 women-years). bFigures in brackets are
counted of women known to be ineligible because of prior breast
cancer diagnosis. Eligibility of screened women was established
prospectively, but ineligibility of control women and non-attenders is
often established retrospectively after death (from breast cancer) has
occurred.
deaths were small and estimates of benefit consequently im-
precise. The estimated mortality reductions are similar to
those for the entire study group. When the calculations
c
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Figwe 1 Cumulative mortality from breast cancer in study (0)
and control (+) groups over 10 years of follow-up: (a) all ages;
(b) aged 45-49 years at survey entry and including updates.
Breast cancer death refers to the underlying cause from death
certificate information (definition 1: see Methods section).
Table I Breast cancer mortality in the initial cohort during 10 years of follow-up
Definition of breast Number of breast Mortality rate/J10,000 Odds ratio (95%
cancer death Trial group cancer deaths women-years at risk confidence interval)
Death certificate Study 105 4.79 0.79
Control 120 5.95 (0.60-1.05)
Underlying cause
Definition Ib Study 96 4.38 0.82
Control 106 5.25 (0.61-1.11)
Definition 2' Study 101 4.61 0.86
Control 108 5.35 (0.66- 1.13)
'Mentioned as a cause of death on the death certificate. 'Breast cancer the underlying cause of death
from death certificate data (either the underlined cause or derived from formal application of WHO
rule 3). 'Breast cancer underlined cause of death on the death certificate or confirmed as underlying
cause - case note review.
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reported in Table III were repeated for the other definitions
of breast cancer death, the results were qualitatively similar.
The mortality reduction for these women did not depend on
whether the age at diagnosis exceeded 50 years.
Breast cancer incidence
Altogether, 489 breast cancers were diagnosed in the 10 year
period in the study population (22.4/10,000 women-years)
and 400 in the controls (20.0/10,000 women-years).
The UICC stage distribution is more favourable for the
study population than for the controls (Table IV); percen-
tages of invasive cancers classified as stages III or IV are
17% and 32% respectively. Cumulative rates (Figure 2a) in
the control group have always exceeded those in the study
group with a 2-fold excess after 10 years. Pathological
classifications of stage I and II cancers by size and node
status confirm the generally favourable characteristics of
cancers in the study group. The cancers are smaller in the
study group and, for each size, the proportions of node-
positive cancers are lower.
Tabar et al. (1985) have combined clinical and pathological
data to define a poor-prognosis tumour category (stage III or
IV, pathological size > 20 mm or node positive). The propor-
tions of invasive cancers which are in this category are 53.5%
and 73.5% for study and control groups respectively; for the
never-screened women the percentage is 80%. However,
approximately half (152 or 47%) of all invasive cancers in
ever-screened women are poor prognosis according to this
definition, and of these 41 (27%) are small node-positive
cancers. Cumulative rates of poor-prognosis cancers (Figure
2b) show excesses in the study group for the first 7 years, but
thereafter a divergence in favour of the study group is emerg-
ing.
The rates of interval cases in the 3 years after the trial
screening ended (Table V) are compared with rates in the
control population the proportional incidence of interval
cases increases markedly with time since the last screen from
12% in the first year to 67% in the third year.
Treatment
Altogether, 55% of women with operable invasive cancer
were treated with adjuvant systemic therapy. This percentage
increased with time from 36% in those diagnosed in study
years 1-5 to 79% for years 6-10. These percentages did not
differ between the two arms of the trial: 53% of the study
group and 57.5% of the control group received adjuvant
therapy. Corresponding figures for the updates were 63.5%
for the study group and 70.3% for the control group.
All-cause mortality and effect ofsocioeconomic status
All-cause mortality in the total trial population was 103.9/
10,000 women-years, which is similar to that expected in a
cohort of Scottish women of this age. The rates in the study
group were 15% lower than in the controls (relative risk =
0.85, 95% confidence interval 0.79-0.92). This difference
cannot be attributed to breast cancer, which represented only
4.7% of all deaths. When the trial population was split into
three groups by SEG of the general practice clusters, the
rates were 84.9, 104.1 and 126.1 with the lowest rates in the
highest SEG; the trend is statistically significant (P<
0.00001). More women in the study population were in the
Table m Breast cancer mortality: further analyses
Number of Mortality
Population Age at entrn Follow-up breast cancer rate/10,000 Odds ratio
studies (years) First year Last year Trial group deaths women-years (95% CIj
Initial cohort 50-64 1 10 Study 79 4.86 0.85
Initial cohort 45-49
Initial cohort
and updates
Control
I 10 Study
Control
Study
1 6,8,10b Control45-49
'Underlying cause of death derived from death certificate data. bFollow-up period available depending on entry
year (see Methods section).
Table IV Classification of breast carcinoma in study and control populations
Study population Control
Pathological Ever Never population
UICC stage classification screeneda screened Total Total
0 TIS 39 3 42 11
IjII 10 mm
No 57 3 60 27
N, 9 2 11 6
Totalb 73 7 80 41
11-20rmm
No 84 14 98 43
N, 32 7 39 28
Totalb 126 24 150 85
21-50 mm
No 54 11 65 45
N, 33 13 46 37
Totalb 88 27 115 96
Size unknown 5 5 10 7
III 16 27 43 76
IV 7 24 31 49
Totalc 364 125 489 400
aThese women accepted at least one invitation to screening during the trial period.
bTotals include those for whom node status is unknown. 'Totals include those for
whom UICC stage is unknown.
85
17
21
25
31
5.77
3.00
3.85
2.57
3.49
(0.62-1.15)
0.77
(0.37-1.62)
0.78
(0.46- 1.31)
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highest SEG group (percentages of women-years were 53%
and 26% in the study and control groups respectively) and
fewer were in the lowest SEG group (27% compared with
42%). Thus the differences in all-cause mortality can be
c
0
E
0
00
0
Q
Co
0.Cu
CD
Years from survey entry
c
0
E
0
0
0
0t
0.Cu
Cu
1 2 3 4 5 6 7 8 9 10
Years from survey entry
Figre 2 Cumulative incidence of breast cancer in the study (0)
and control (+) groups over 10 years of follow-up: (a) UICC
clinical staging III, IV; (b) advanced disease as defined by Tabar
et al., 1985.
Table V Cases arising during the 3 year interval' between trial and
service screens
Times from
negative screen Rate'10,000 Proportion of
(months) Number of cases women-Years control incidence
0-11 2 2.0 0.12
12-23 7 7.1 0.42
24-35 11 11.3 0.67
36 or over 4 11.1 0.65
Total 24 7.3 0.43
'This is restricted to women who were still in regular screening in
year 7 of the trial.
explained at least in part by socioeconomic classifications. It
was not possible to calculate an overall RR for breast cancer
mortality with adjustment for practice SEG because of a
statistically significant interaction (P<0.005) between arm of
the trial and SEG. Since SEG is applied to GP practices
rather than individual women, the imbalance between the
two arms of the trial is independent of age.
These results based on 10 years of follow-up confirm our
earlier findings (Roberts et al., 1990). There is a reduction in
breast cancer mortality of around 18% in the total study
population. This is not statistically significant and the
confidence intervals are wide so that, by themselves, the
results are inconclusive. They should be interpreted in con-
text and are consistent with the consensus (Wald et al., 1991)
that mammographic screening reduces breast cancer mor-
tality but by rather less than the 30% originally found in the
HIP study (Shapiro et al., 1982) and later by the Swedish
two-counties trial (Tabar et al., 1985). Other trials in Sweden
have achieved smaller reductions, and the recent Swedish
overview (Nystrom et al., 1993) which includes all the
Swedish trials estimates the reduction at 12 years of follow-
up to be 22%; this is based on 882 deaths and is highly
statistically significant. No other randomised trials of mam-
mographic screening using an unscreened control group have
been conducted outside Sweden since the HIP study, which
was started in 1967. The Edinburgh trial, though numerically
small, provides useful indications that the benefits observed
in Sweden can be achieved elsewhere. This is important since
the breast cancer experience in Sweden is very different; for
example, cumulative mortality in the Edinburgh study group
after 10 years (4.38/10,000 women-years) exceeded that in the
Swedish two-counties control group after 12 years (4.151
10,000 women-years, from Nystrom et al., 1993).
The TEDBC is larger than the Edinburgh trial but is a
geographical comparison. Our data are not independent since
the Edinburgh study group contributes to the TEDBC; the
controls are, however, entirely distinct. Estimated reductions
in breast cancer mortality for the TEDBC of 20% have
recently been reported (UK Breast Cancer Detection Work-
ing Group, 1993); these are statistically significant but rely on
difficult adjustments using pretrial breast cancer standardised
mortality ratios (SMRs) for the geographical regions.
A number of design or execution problems for the study
have been discussed previously (Roberts et al., 1990) but
should be noted here; these include the attendance rate,
mammographic quality in the early years, loss of efficiency
from cluster rather than individual randomisation and statis-
tical power. All of these will have a conservative effect. Other
potential sources of bias were, firstly, different use of
adjuvant systemic therapy (Early Breast Cancer Trialists Col-
laborative Group, 1992) between the two groups and,
secondly, differential errors of ascertainment of breast cancer
deaths. We have demonstrated that the first does not apply
and our methods of ascertainment avoid the latter.
Establishing whether death is attributable to breast cancer
is difficult in a small number of cases. The review of a
random sample of deaths with breast cancer underlined on
the death certificate has confirmed previous findings: over-
estimation of breast cancer as a cause of death of around 6%
(Brinkley et al., 1984; UK Breast Cancer Detection Working
Group, 1991). The review of case notes reveals that small
errors have occurred in the classification of the remaining
deaths of breast cancer patients, but these data are compati-
ble with other recommendations (Brinkley et al., 1984) that
analyses should use death certificate classifications of the
underlying cause of death. Non-differential misclassification
in the data will be a further source of conservative bias.
An unexpected consequence of the use of cluster sampling
is the bias between the two arms of the trial, which is
evidenced in the differences in all-cause mortality. This is in
part explained by lower socioeconomic status in the control
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group (Alexander et al., 1989). There is a body of evidence
demonstrating that the direction of the association of
socioeconomic status with breast cancer is opposite to that
for all-cause mortality (Tomatis et al., 1990; Scottish Breast
Screening Progamme, 1993). Tlhis suggets that the bias
should be conservative, but our data have not permitted
formal adjustment of the analyses for the effect of
socioeconomic status. Despite the possibility of confounding
in this study and inadequac of SMR adjustment in the
TEDBC, the point estimates from the two studies are very
similar.
We conclude that our findings support the prevailing view
that mammographic screening does reduce mortality from
breast cancer - at least in women screelKe when 50 years and
over (Wald et al., 1991). Our data do not indicate that this
age range fared better than the younger women.
There is currently no consensus on the merits of screening
younger women (Beral, 1993; Elwood et al., 1993; Fkltcher et
al., 1993). The principal difficulty is that no trial of tradi-
tional design has been conducted with sufficient statistical
power to analyw this age group separately. In addition, most
authors fail to distnguiish between the short and longer
follow-up periods. For short follow-up periods (i.e. 7 years or
less) all publishd trial results give point estimates of the
relative risk which are either close to unity or exceed it
(Shapiro et al., 1982; Miler et al., 1992; Nystrom et al.,
1993). This is supported by the Malmo trial (Andersson et
al., 1988) and the only relevant case-control study (Verbeek
et al., 1985). For longer follow-up periods the HIP trial
reported reductions in breast cancer mortality for younger
women (first screened when 40-49 years) which was even-
tually of the same magnitude as that in older women
(Shapiro et al., 1988) and, in one analysis (Chu et al., 1988),
achieved statistical signifi . This is the only trial with
follow-up exceeding 12 years but the Swedish tials have now
reported a reduction of 13% after 12 years. Similar rmsults
have been reported by the Breast Cancer Demonstration
Project, although this latter is neither population based nor
randomised (Morrison et al., 1988).
The Edinburgh rsults are consistent with the emerging
consensus that modest reductions in breast cancr mortality
are achieved for women first screened when under 50 years,
but the benefits appear later than those for okler women. At
7 years breast cancer mortality for women in the youngest
age group was almost identical for the two arms of the trial.
Now there is a reduction of 22% in the study group, but this
does not approach statistical signiicance. These results with
a randomised design and independent controls confirm the
findings of the TEDBC [relative risk = 0.74 (0.54-1.0)] (UK
Breast Cancer Detection Workcing Group, 1993). The data
cannot be interpreted as evidence for population screening
for younger women; they do, however, indicate that the
optimal age to commence screning remains unknown; this is
an important public health question which requires resolu-
tion by further randomised trials.
The classification of breast cancers by clinical stage and by
pathological size and node status reveals an encouraging
difference between study and control groups but is disappoin-
ting in one critical respect. This is the failure of screening to
reduce the incidence of poor-prognosis disease as defined by
Tabar et al. (1985) and, in particular, to achieve major
reductions in the frequency of nodal metastases amongst the
smaller cancers (t<20 mm). Half of all invasive cancers in
ever-screened women are poor prognosis compared with 33%
in the Swedish two-counties trial (Tabar et al., 1985). In both
trials the percentages in the never-screened women (80% and
73% respectively) exceeded those in the controls, but the
impact on the total study group is greater in Edinburgh on
account of the lower attendance rate. The cumulative
incidence of this poor-prognosis disease is not substantially
reduced in the Edinburgh study group - although the results
for the years 8-10 give preliminary indications that the
curves may be diverging strongly. In the two-counties trial
the changing incidence was reflected by the mortality curve
(Tabar et al., 1985), and subsequent analyses (Tabar et al.,
1992) have demonstrated that it is strongly predictive of
mortality. Much of the failure of our mortality reduction to
increase between 7 and 10 years of follow-up is likely to be
explained by delay in this aspect of performance. Although
we have detected large numbers of in situ cancer, this is
predicted to have less impact on mortality than reducing the
rate of small node-positive cancers (Tabar et al., 1992). One
of the strengths of the present trial database is that high
achievement in pathological classifictions of nodal status
within one city has permitted an analysis which identifies the
problem more clearly than is possible using tumour size
alone (UK Breast Cancer Detection Working Group,
1993).
When service screeing was introduced into Edinburgh we
took the opportunity of designing a protocol which would
enable us to report on the interval cancer rates over 3 years
in regularly screened women; these should be predictive of
eventual rates in the service programme with its 3 yearly
schedule. The optimum interval between examinations is
unknown; a randomised trial comparing 1 yearly intervals
with 3 yearly ones is currently in progress (N. Day, personal
communication) but will not report for several years. Mean-
while, the best method of evaluating the inter-screening inter-
val is to compare the proportional incidence of interval cases
across the period (Tabar et al., 1987). The proportions we
report are based on small numbers but exceed those for the
two-counties trial in both the second (42% compared with
29%) and third (67% compared with 45%) year (Tabar et
al., 1987). This indicates, firstly, that the interval could be
too long and should certainly not exceed 3 years - for the
population or for individual women. Secondly, it may be
further evidence that screening as practised during the trial
lacked sensitivity for detecting biologically important
cancers.
In conclusion, this trial has provided modest but important
contributions to the overall scientific evaluation of mammo-
graphic sceening. These include further evidence that screen-
ing - at least for women over 50 years - can reduce mortality
from breast cancer by around 20%. With current standards
of mammography and higher attendance rates larger reduc-
tions may be achievable. The extension of results from
scientific trials to routine health care can be problematic, but
current reports from UK service screening are encouraging
(Chamberlain et al., 1993; Scottish Breast Screening Pro-
gramme, 1993). Thr is a need to determine the best age for
screening to commence. Since the benefits of screening take
at least 4 years to emerge, the present service screening
programme though targeted at women of 50 years and over
will have little impact on mortality from the disease in
women aged 50-54 years despite the fact that 20% of all
deaths of British women in this age group are due to breast
cancer (OPCS, 1989-93).
Finally, two warning messages emerge from this study:
firstly, follow-up and recall facilities must ensure that
minimal numbers of women wait for more than 3 years
between their invitations to screening. Secondly, screening
targets must focus on detection of cancers before nodal
metastases develop rather than relying on favourable size. It
follows that it is essential to the monitoring of the UK
service screeing programme that histological evidence of
node status is available on all cases arising in the target
population.
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